Dr Reddy’s, India’s third-largest listed pharmaceutical company by market capitalisation, posted a steady performance for the December quarter.
Within emerging markets, the rest of the world segment saw sharp 46 per cent growth aided by product launches and higher sales volumes for the base business.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world.